Cargando…
NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
Autores principales: | Piepiorka-Broniecka, Marta, Michalski, Tomasz A., Figatowski, Tomasz, Wojtowicz, Andrzej, Jurowiecki, Jarosław, Stanska, Aleksandra, Rogowski, Jan, Jaguszewski, Milosz J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007476/ https://www.ncbi.nlm.nih.gov/pubmed/34897639 http://dx.doi.org/10.5603/CJ.a2021.0158 |
Ejemplares similares
-
ST-segment elevation myocardial infarction after COVID-19 reinfection: The disseminated thrombotic process
por: Michalski, Tomasz A., et al.
Publicado: (2021) -
Transfermoral aortic valve implantation using self-expanding New Valve Technology (NVT) Allegra bioprosthesis: A pilot prospective study
por: Jagielak, Dariusz, et al.
Publicado: (2021) -
Premature Bioprosthetic Mitral Valve Dysfunction Due to Flail Leaflet Treated With Transcatheter Mitral Valve Replacement; a Case Report
por: Munoz, Carlos, et al.
Publicado: (2022) -
Thrombolysis for Cardiogenic Shock Secondary to Aortic Bioprosthetic Valve-in-Valve Thrombosis
por: Chu, Jian, et al.
Publicado: (2022) -
Granulicatella adiacens Endocarditis of a Bioprosthetic Aortic Valve
por: Warren, Amanda, et al.
Publicado: (2023)